US20120289690A1 - Nucleic acid elution - Google Patents
Nucleic acid elution Download PDFInfo
- Publication number
- US20120289690A1 US20120289690A1 US13/519,391 US201013519391A US2012289690A1 US 20120289690 A1 US20120289690 A1 US 20120289690A1 US 201013519391 A US201013519391 A US 201013519391A US 2012289690 A1 US2012289690 A1 US 2012289690A1
- Authority
- US
- United States
- Prior art keywords
- dna
- solid matrix
- matrix
- inulin
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000039446 nucleic acids Human genes 0.000 title claims description 5
- 108020004707 nucleic acids Proteins 0.000 title claims description 5
- 150000007523 nucleic acids Chemical class 0.000 title claims description 5
- 238000010828 elution Methods 0.000 title description 4
- 239000011159 matrix material Substances 0.000 claims abstract description 51
- 239000007787 solid Substances 0.000 claims abstract description 37
- 229920001202 Inulin Polymers 0.000 claims abstract description 20
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 20
- 229940029339 inulin Drugs 0.000 claims abstract description 20
- 239000000872 buffer Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 abstract description 4
- 229920001282 polysaccharide Polymers 0.000 abstract description 4
- 239000005017 polysaccharide Substances 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 15
- 238000011084 recovery Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- -1 DNA Chemical class 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- This invention relates to the storage on a solid matrix of genetic material, in particular DNA that has been purified prior to the application to the solid matrix.
- Burgoyne (WO 90/03959) described a method whereby biological samples, usually blood, could be applied to a solid matrix which combined reagents which lysed the cells. The released DNA was retained on the solid matrix. These samples could be stored for long periods at room temperature.
- inulin a polysaccharide found in plants
- FIG. 1 shows the structure of inulin.
- PEG is prepared in a variety of molecuar weights defined by the average number of subunits per molecule. Polymers of MW 400, 1000 and 3350 were evaluated. It was observed that PEG 1000 produced the best recovery of applied DNA results (data not shown) and was used in the remainder of the tests but is referred to as PEG. At concentration of PEG at about 25% the results varied between experiments; this may imply small inconsistencies in the coating process of the solid matrix at these concentrations.
- Inulin is a naturally occurring polysaccharide found in many plants. Its structure is given in FIG. 1 . it is anticipated that simple modifications of inulin eg esterification would be possible and still achieve the improved elution of the applied purified DNA.
- the purified DNA can be applied to the solid matrix that has been treated with inulin in buffers that are routinely used in nucleic acid chemistry. Up to 10% PEG can also be included in the application buffer.
- the DNA prior to application to the solid matrix can be purified by a variety of standard laboratory techniques.
- the solid matrix was FTA Elute 903 matrix from Whatman.
- a 4 M stock of guanidine thiocyanate was prepared and diluted to 2 M using various concentrations of test reagents.
- 903 matrix (2 ⁇ 2 1 ⁇ 4′′) was placed into trays containing guanidine thiocyanate/test reagent mixes and agitated gently for 10 seconds.
- Matrices were dried for 10 min on a metal rack using two hair dryers (Simply Basic DS-727); one placed at a 30° angle 15 cm above the matrix, the other placed 25 cm below the matrix at a 30° angle such that the two hair dryers and the matrix were in alignment. Matrices were dried further without the air flow at 21 ⁇ 2° C. overnight. 4) Matrices were stored at room temperature in a desiccator until use.
- Human DNA (Roche) was spotted onto the test solid matrix at concentration of 160 ng/ ⁇ l. Usually a pre-punched 5 mm diameter disc of the matrix was used. Discs were dried at room temperature for a minimum of 3 hours.
- Quantification of DNA in eluates was performed by QPCR using a 7900HT Thermal Cycler (Applied Biosystems). Reactions were set up using an RNase P assay and TAQMAN® Universal PCR Master Mix (Applied Biosystems). A four point standard curve was prepared using a serial dilution from 10 to 0.01 ng/ ⁇ l of the same Roche DNA used for experiments. Early QPCR quantifications were performed in 96-well plates and were set up manually. Following the introduction and validation of a liquid handling robot, later quantifications were performed using 384-well plates. Both 96 and 384-well plates were validated and also tested against each other to check for consistency between methods.
- Results show that matrices impregnated with either inulin or PEG did 20 result in increased DNA recovery compared to FTA Elute by itself.
- the use of a spotting buffer containing 10% PEG resulted in an additional increase in DNA yield (85% when used with FTA Elute+20% inulin).
- the matrix containing 20% inulin showed the highest % recovery of applied purified DNA. Since PEG was also identified as a possible additive to matrix impregnation chemistry, FTA Elute impregnated with a combination of 20% inulin and 10% PEG was also prepared for further investigation. A spotting buffer containing 10% PEG was confirmed as further increasing yields when used in conjunction with the modified matrix chemistry.
- Results were also obtained from experiments where the discs with applied purified DNA had been stored in a dessicator at room temperature. The results showed that the discs could be stored for at least twenty-three days before DNA elution with similar increased recovery of DNA when the matrix had been treated with inulin.
- Results also showed that the amount of DNA applied and recovered from the test matrix could be as low as 1 ng and as high as 1 ⁇ g (the maximum tested) and the increased effect on inulin treatment was still observed.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/519,391 US20120289690A1 (en) | 2009-12-29 | 2010-12-21 | Nucleic acid elution |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29065209P | 2009-12-29 | 2009-12-29 | |
| PCT/EP2010/070389 WO2011080160A1 (en) | 2009-12-29 | 2010-12-21 | Improvements to nucleic acid elution |
| US13/519,391 US20120289690A1 (en) | 2009-12-29 | 2010-12-21 | Nucleic acid elution |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2010/070389 A-371-Of-International WO2011080160A1 (en) | 2009-12-29 | 2010-12-21 | Improvements to nucleic acid elution |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/122,606 Division US11725201B2 (en) | 2009-12-29 | 2020-12-15 | Nucleic acid elution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20120289690A1 true US20120289690A1 (en) | 2012-11-15 |
Family
ID=43743431
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/519,391 Abandoned US20120289690A1 (en) | 2009-12-29 | 2010-12-21 | Nucleic acid elution |
| US17/122,606 Active 2031-08-03 US11725201B2 (en) | 2009-12-29 | 2020-12-15 | Nucleic acid elution |
| US18/340,609 Active US12247199B2 (en) | 2009-12-29 | 2023-06-23 | Nucleic acid elution |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/122,606 Active 2031-08-03 US11725201B2 (en) | 2009-12-29 | 2020-12-15 | Nucleic acid elution |
| US18/340,609 Active US12247199B2 (en) | 2009-12-29 | 2023-06-23 | Nucleic acid elution |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120289690A1 (enExample) |
| EP (1) | EP2519631B1 (enExample) |
| JP (1) | JP5899118B2 (enExample) |
| CN (1) | CN102725406B (enExample) |
| AU (1) | AU2010338349B2 (enExample) |
| CA (1) | CA2785913C (enExample) |
| WO (1) | WO2011080160A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9534214B2 (en) | 2013-10-31 | 2017-01-03 | General Electric Company | Substrates and associated methods for elution of nucleic acids |
| US9719082B2 (en) | 2013-10-31 | 2017-08-01 | General Electric Company | Substrates and associated methods for elution of nucleic acids |
| US10625242B2 (en) | 2012-04-30 | 2020-04-21 | General Electric Company | Substrates and methods for collection, stabilization and elution of biomolecules |
| US10638963B2 (en) | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
| US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
| US11795446B2 (en) | 2020-03-23 | 2023-10-24 | Ricoh Company, Ltd. | Carrier and testing method |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2785913C (en) * | 2009-12-29 | 2019-05-21 | Ge Healthcare Bio-Sciences Corp. | Improvements to nucleic acid elution |
| US10000742B2 (en) * | 2015-11-19 | 2018-06-19 | General Electric Company | Device and method of collection for RNA viruses |
| CN105462961B (zh) * | 2016-01-14 | 2019-04-19 | 苏州市公安局 | 一种提取核酸的方法及试剂盒 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124444A (en) * | 1989-07-24 | 1992-06-23 | Microprobe Corporation | Lactam-containing compositions and methods useful for the extraction of nucleic acids |
| WO2003044211A2 (en) * | 2001-11-15 | 2003-05-30 | Whatman Inc. | Materials and methods for releasing genetic material |
| US20060147944A1 (en) * | 2005-01-04 | 2006-07-06 | Piotr Chomczynski | Reagents and methods for storage and processing of biological samples for DNA analysis |
| US20060153920A1 (en) * | 2004-09-24 | 2006-07-13 | Ketan Amin | Lyophilized pharmaceutical compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003959A1 (en) | 1988-10-05 | 1990-04-19 | The Flinders University Of South Australia | Solid medium and method for dna storage |
| US5496562A (en) * | 1988-10-05 | 1996-03-05 | Flinders Technologies Pty Ltd | Solid medium and method for DNA storage |
| GB8903593D0 (en) * | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| US5939259A (en) | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
| AU4353500A (en) * | 1999-04-30 | 2000-11-17 | Whatman, Inc. | Substrate including anionic detergent for purifying nucleic acid |
| SE9904475D0 (sv) * | 1999-12-08 | 1999-12-08 | Artursson | Nucleic acid delivery system |
| JP3776334B2 (ja) * | 2001-07-11 | 2006-05-17 | 株式会社富士薬品 | イヌリン含有製剤 |
| EP1436405A4 (en) | 2001-08-20 | 2006-01-04 | Whatman Inc | CLEANING AND OBTAINING DNA FROM HIGH-PARTICLES AND SOLIDS SAMPLES |
| DK1442045T3 (da) * | 2001-11-06 | 2009-02-09 | Cortex Biochem Inc | Isolering og oprensning af nukleinsyrer |
| US20040033546A1 (en) * | 2002-04-10 | 2004-02-19 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
| KR20070011236A (ko) * | 2003-10-23 | 2007-01-24 | 알자 코포레이션 | 미세돌출부 코팅용의 ｄｎａ 안정화 조성물 |
| CA2785913C (en) * | 2009-12-29 | 2019-05-21 | Ge Healthcare Bio-Sciences Corp. | Improvements to nucleic acid elution |
-
2010
- 2010-12-21 CA CA2785913A patent/CA2785913C/en active Active
- 2010-12-21 EP EP10796044.5A patent/EP2519631B1/en active Active
- 2010-12-21 AU AU2010338349A patent/AU2010338349B2/en active Active
- 2010-12-21 US US13/519,391 patent/US20120289690A1/en not_active Abandoned
- 2010-12-21 CN CN201080059859.XA patent/CN102725406B/zh active Active
- 2010-12-21 JP JP2012546416A patent/JP5899118B2/ja active Active
- 2010-12-21 WO PCT/EP2010/070389 patent/WO2011080160A1/en not_active Ceased
-
2020
- 2020-12-15 US US17/122,606 patent/US11725201B2/en active Active
-
2023
- 2023-06-23 US US18/340,609 patent/US12247199B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124444A (en) * | 1989-07-24 | 1992-06-23 | Microprobe Corporation | Lactam-containing compositions and methods useful for the extraction of nucleic acids |
| WO2003044211A2 (en) * | 2001-11-15 | 2003-05-30 | Whatman Inc. | Materials and methods for releasing genetic material |
| US20060153920A1 (en) * | 2004-09-24 | 2006-07-13 | Ketan Amin | Lyophilized pharmaceutical compositions |
| US20060147944A1 (en) * | 2005-01-04 | 2006-07-06 | Piotr Chomczynski | Reagents and methods for storage and processing of biological samples for DNA analysis |
Non-Patent Citations (2)
| Title |
|---|
| de Jonge et al. (European Journal of Pharmaceutical Sciences (2007), 32(1), 33-44) * |
| Kravchenko et al. (Russian Journal of Bioorganic Chemistry, 2006, Vol. 32, No. 6, pp. 547–551). * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10625242B2 (en) | 2012-04-30 | 2020-04-21 | General Electric Company | Substrates and methods for collection, stabilization and elution of biomolecules |
| US9534214B2 (en) | 2013-10-31 | 2017-01-03 | General Electric Company | Substrates and associated methods for elution of nucleic acids |
| US9719082B2 (en) | 2013-10-31 | 2017-08-01 | General Electric Company | Substrates and associated methods for elution of nucleic acids |
| US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
| US10638963B2 (en) | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
| US10888259B2 (en) | 2017-01-10 | 2021-01-12 | Drawbridge Health, Inc. | Cartridge assemblies for storing biological samples |
| US10932710B2 (en) | 2017-01-10 | 2021-03-02 | Drawbridge Health, Inc. | Carriers for storage and transport of biological samples |
| US11298060B2 (en) | 2017-01-10 | 2022-04-12 | Drawbridge Health, Inc. | Devices for collecting biological samples |
| US11795446B2 (en) | 2020-03-23 | 2023-10-24 | Ricoh Company, Ltd. | Carrier and testing method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5899118B2 (ja) | 2016-04-06 |
| WO2011080160A1 (en) | 2011-07-07 |
| AU2010338349A1 (en) | 2012-06-21 |
| CA2785913A1 (en) | 2011-07-07 |
| CN102725406A (zh) | 2012-10-10 |
| US11725201B2 (en) | 2023-08-15 |
| EP2519631A1 (en) | 2012-11-07 |
| JP2013515494A (ja) | 2013-05-09 |
| EP2519631B1 (en) | 2017-02-15 |
| US20210102190A1 (en) | 2021-04-08 |
| AU2010338349B2 (en) | 2015-03-05 |
| US20230332133A1 (en) | 2023-10-19 |
| CA2785913C (en) | 2019-05-21 |
| US12247199B2 (en) | 2025-03-11 |
| CN102725406B (zh) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12247199B2 (en) | Nucleic acid elution | |
| US10472620B2 (en) | Method, substrate and device for separating nucleic acids | |
| EP2021508B1 (en) | Ambient temperature stable kits for molecular diagnostics | |
| US20160002622A1 (en) | Methods for capturing nucleic acids | |
| ES2355899T3 (es) | Procedimientos, kits y dispositivos de tratamiento de ácidos nucleicos. | |
| EP2432873B1 (en) | A dried and stabilized ready-to-use composition containing nucleic acid polymerization enzymes for molecular biology applications | |
| Ozkan et al. | Comparative evaluation of RNAlater solution and snap frozen methods for gene expression studies in different tissues | |
| JP2023138629A (ja) | 核の保存方法 | |
| EP3164511B1 (en) | Methods for amplifying nucleic acids on substrates | |
| EP3230477B1 (en) | Methods for capturing nucleic acids | |
| EP1356122B1 (en) | Ammonium sulfate for neutralization of inhibitory effects | |
| WO2025099161A2 (en) | Dry storage | |
| KR20250020999A (ko) | 혈액 시료 내 성분 고정을 위한 조성물 | |
| WO2008145708A2 (de) | Aromatische alkohole zur behandlung einer biologischen probe | |
| HK1146831A (en) | Ambient temperature stable kits for molecular diagnostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: WHATMAN, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAGE, ANDREW FRANCIS;PARKER, BRECK OLLAND;REEL/FRAME:028451/0342 Effective date: 20110201 Owner name: GE HEALTHCARE BIO-SCIENCES CORP., NEW JERSEY Free format text: MERGER;ASSIGNOR:WHATMAN, INC.;REEL/FRAME:028451/0372 Effective date: 20110228 |
|
| STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
| STCV | Information on status: appeal procedure |
Free format text: BOARD OF APPEALS DECISION RENDERED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| AS | Assignment |
Owner name: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC, MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:GE HEALTHCARE BIO-SCIENCES CORP.;REEL/FRAME:053648/0854 Effective date: 20190930 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |